Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC Effectiveness in Nampula, Mozambique
NCT05186363Phase 4Unknown
- Sponsor
- Malaria Consortium
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sulfadoxine, pyrimethamine and amodiaquine in malaria, sponsored by Malaria Consortium. Primary endpoints: Incidence of confirmed malaria cases at 4 months and Chemopreventive efficacy of SPAQ at 1 month. Status: unknown.
02
Drugs
sulfadoxinepyrimethamineamodiaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05186363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186363.